Equal-WT
WhaleScore 2.0
?
AVORO CAPITAL ADVISORS LLC
NEW YORK NY
Investment Advisor
Hedge Fund
Activist Investor
Avoro Capital Advisors is based out of New York. Avoro Capital Advisors is a hedge fund with 3 clients and discretionary assets under management (AUM) of $8,737,904,424 (Form ADV from 2024-06-04). Their last reported 13F filing for Q3 2024 included $6,858,151,355 in managed 13F securities
and a top 10 holdings concentration of 69.62%. Avoro Capital Advisors's largest holding is United Therapeutics Corp with shares held of 2,858,888. Whalewisdom has at least 40 13F filings, 14 13D filings, 140 13G filings, and 23 Form 4 filings
Business Description
Avoro Capital Advisors LLC (AVCAP) is a registered investment adviser with the SEC. The firm provides advisory services to private investment funds, which in turn invest in portfolio companies. AVCAP may acquire control positions in portfolio companies, along with certain contractual rights to protect its investments. However, AVCAP may not always have control over its portfolio companies, and management or shareholders of portfolio companies may refuse to adopt the recommendations of AVCAP.
AVCAP's advisory services include providing investment advice, conducting due diligence on potential investments, and monitoring portfolio companies. AVCAP may also provide other services to portfolio companies, such as financial planning and operational support. AVCAP charges fees for its advisory services, which are typically based on a percentage of the assets under management.
Investment Strategy
The Life Sciences Funds aim for moderate risk and attractive returns by investing primarily in equity, debt, and derivatives of companies in the life sciences sector and related industries. The investment program is speculative, with no guarantee of achieving the investment objective.
The Funds' investment strategies involve fundamental analysis, including financial statement reviews, management team interviews, background checks, discussions with industry participants, and evaluation of price levels. Investments are typically long or short positions in equity, debt, or convertible securities and derivatives. The Funds may also make follow-on investments in portfolio companies, but there is no assurance that they will do so or have sufficient funds.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-09-30
Top Buys (13F)
| Name | % Change |
|---|---|
| ASND Ascendis Pharma A/S | 3.24% |
| KYMR Kymera Therapeutics, | 1.56% |
| PCVX Vaxcyte, Inc | 1.38% |
| RNA Avidity Biosciences, | 1.07% |
| KRYS Krystal Biotech Inc | 1.01% |
2024-09-30
Top Sells (13F)
| Name | % Change |
|---|---|
| CERE Cerevel Therapeutics | 4.11% |
| XBI SPDR Biotech ETF | 3.75% |
| BMRN BioMarin Pharmaceuti | 2.91% |
| SRPT Sarepta Therapeutics | 1.66% |
| MDGL Madrigal Pharmaceuti | 1.39% |
2024-09-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| UTHR United Therapeutics | 14.94% |
| ASND Ascendis Pharma A/S | 10.86% |
| ARGX Argenx SE ADS ADR | 9.79% |
| KRYS Krystal Biotech Inc | 6.96% |
| MDGL Madrigal Pharmaceuti | 6.28% |
2024-09-30
13F Activity
| Market Value | $6.86b, Prior: $7.51b |
| Inflows (Outflows) as % of Total MV | (-11.133)% |
| New Purchases | 1 stocks |
| Added To | 10 stocks |
| Sold out of | 6 stocks |
| Reduced holdings in | 8 stocks |
| Top 10 Holdings % | 69.62% |
| Turnover %[1] | 16.67% |
| Turnover Alt %[2] | 4.39% |
| Time Held Top 20 | 11.9 quarters |
| Time Held Top 10 | 9.5 quarters |
| Time Held All | 12.64 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-09-30